https://slavyanski.net/sb2020/story.php?title=assessment-of-the-bioactivity-of-adalimumab-should-include-assessment-of-multiple-6 Assessment of the bioactivity of adalimumab should include assessment of multiple in vitro endpoints (NFjB-dependent and NFjB-independent) and should include binding to both soluble and transmembrane TNFa. ABP 501 has been shown to be similar to adalimumab in its ability to neutralize TNFa-induced caspase activation, chemokine production, and cytotoxicity, functions inclusive of both NFjB-dependen Fri, 07 Aug 2020 09:46:51 UTC en